a Multicenter, Randomized, Open-label, Active-treatment, Controlled Trial to Compare the Efficacy of NOAC With Edoxaban vs. Dual Antiplatelet Therapy (DAPT) for Prevention of Leaflet Thrombosis (Documented by Cardiac CT Imaging) and Cerebral Embolization (Documented With Brain DW-MRI Imaging) in Patients Without an Absolute Indication for Chronic OAC After Successful TAVR

Trial Profile

a Multicenter, Randomized, Open-label, Active-treatment, Controlled Trial to Compare the Efficacy of NOAC With Edoxaban vs. Dual Antiplatelet Therapy (DAPT) for Prevention of Leaflet Thrombosis (Documented by Cardiac CT Imaging) and Cerebral Embolization (Documented With Brain DW-MRI Imaging) in Patients Without an Absolute Indication for Chronic OAC After Successful TAVR

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Feb 2018

At a glance

  • Drugs Edoxaban (Primary) ; Aspirin; Clopidogrel
  • Indications Intracranial embolism; Thrombosis
  • Focus Therapeutic Use
  • Acronyms ADAPT-TAVR
  • Most Recent Events

    • 31 Jan 2018 Planned initiation date changed from 1 Jan 2018 to 1 Feb 2018.
    • 10 Dec 2017 Planned initiation date changed from 1 Nov 2017 to 1 Jan 2018.
    • 19 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top